Lawrence M. Blatt

机构：Rapt Therapeutics (United States), Denali Therapeutics (United States) · ORCID：0000-0002-6442-9207

发表论文 200 篇 · 总被引 7121 次 · h-index 44

代表论文

• Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH (2024 · Journal of Medicinal Chemistry · 被引 35)
• The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075 (2024 · Journal of Medicinal Chemistry · 被引 28)
• Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor (2025 · Journal of Medicinal Chemistry · 被引 4)
• A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants (2025 · Antiviral Therapy · 被引 3)
• A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants (2025 · Clinical Pharmacology in Drug Development · 被引 3)
• WED-365 Extended treatment of HBeAg+ CHB subjects with the Capsid assembly modulator ALG-000184 with or without Entecavir is associated with reductions in viral markers and favorable anti-HBeAb trends (2024 · Journal of Hepatology · 被引 3)